In a retrospective German cohort, 26 out of 61 (43%) patients with anti-LGI1, 11 out of 25 (44%) with anti-CASPR2, 31 out of 84 (37%) with anti-glutamic acid decarboxylase 65 (GAD65), and 81 out of 142 (57%) with anti-NMDAR encephalitis were treated with rituximab [22]. This evidence concerns the gene LGI1 and viral encephalitis.